New oncology partnership for French drugmaker Ipsen

4 May 2020
ipsen-logo-big

French drugmaker Ipsen (Euronext: IPN) has bought an option on an oncology program from Montreal-based biotech group, IRICoR.

Based at the Institute for Research in Immunology and Cancer (IRIC), IRICoR is a pan-Canadian research commercialization center based at the Université de Montreal, Canada.

The option agreement gives Ipsen rights to acquire an exclusive global license for the program, which is currently at lead optimization stage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology